A-ha frontman Morten Harket reveals Parkinson's diagnosis
The 'Take On Me' singer told biographer Jan Omdahl that he underwent a procedure for deep brain stimulation (DBS) in June 2024, addressing the left side of his brain, and a similar one in December for the right.
Parkinson's causes parts of one's brain to deteriorate and affects muscle control, balance and movement, as well as thinking ability and mental health, according to the Cleveland Clinic.
'The simple fact that, on good days, Morten shows virtually no sign of many of the most familiar physical symptoms of Parkinson's, doesn't mean that he is well,' wrote Omdahl, who penned the Norwegian band's 2003 biography, 'The Swing of Things.'
Omdahl recounted Harket's 'round-the-clock effort to balance medication, signals from the electrodes in his brain, sleep, blood sugar and mindset in a way that keeps the symptoms and side effects more or less in check,' though it 'isn't always successful.'
Harket said he doesn't 'expect to be able to achieve full technical control' of his voice anymore, even as he works on unreleased music.
'The question is whether I can express myself with my voice,' he told Omdahl. 'As things stand now, that's out of the question.'
Harket, however, told fans not to worry and instead 'spend your energy and effort addressing real problems, and know that I am being taken care of.'
A-ha — a synth-pop trio whose members also include Magne Furuholmen and Paul Waaktaar-Savoy — is best known for their 1980s hits 'Take On Me,' 'Cry Wolf' and 'The Sun Always Shines on TV.' The band split in 2009 but briefly reunited in 2015.
The music video for 'Take On Me' hit 1 billion views in early 2020 and crossed the 2 billion-view threshold this past September.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WIRED
2 hours ago
- WIRED
An AI Model for the Brain Is Coming to the ICU
Aug 11, 2025 11:00 AM The Cleveland Clinic and startup Piramidal are developing an AI model trained on brain wave data to monitor intensive care patients. The Cleveland Clinic is partnering with San Francisco-based startup Piramidal to develop a large-scale AI model that will be used to monitor patients' brain health in intensive care units. Instead of being trained on text, the system is based on electroencephalogram (EEG) data, which is collected via electrodes placed on the scalp and then read out by a computer in a series of wavy lines. EEG records the brain's electrical activity—and changes in this activity can indicate a problem. In an ICU setting, doctors scan EEG data looking for evidence of seizures, altered consciousness, or a decline in brain function. Currently, doctors rely on continuous EEG monitoring to detect abnormal brain activity in an ICU patient, but they can't monitor every individual patient in real time. Instead, EEG reports are typically generated every 12 or 24 hours and then analyzed to determine whether a patient is experiencing a neurological issue. It can take two to four hours to manually review a day's worth of brainwave data. 'This type of thing is time-consuming. It is subjective, and it is experience- and expertise-dependent,' says Imad Najm, a neurologist and director of the Epilepsy Center at the Cleveland Clinic's Neurological Institute. The system that the Cleveland Clinic and Piramidal are developing is designed to interpret continuous streams of EEG data and flag abnormalities in seconds so that doctors can intervene sooner. 'Our model plays that role of constantly monitoring patients in the ICU and letting the doctors know what's happening with the patient and how their brain health is evolving in real-time,' says Piramidal's chief product officer Kris Pahuja. Pahuja and CEO Dimitris Fotis Sakellariou founded Piramidal in 2023, with the goal of building a foundation model for the brain—an AI system that can read and interpret neural signals broadly across different people. Prior to this, Sakellariou spent 15 years as a neuroengineer and AI scientist doing EEG research. Pahuja worked on product strategy at Google and Spotify. Their startup, which is backed by Y Combinator, raised $6 million in seed funding last year. The company built its ICU brain model using publicly available EEG datasets, as well as proprietary EEG data from the Cleveland Clinic and other partnerships. Sakellariou says the model incorporates nearly a million hours of EEG monitoring data from 'dozens of thousands' of patients, both neurologically healthy and unhealthy. Brain activity patterns are extremely variable from person to person, so building a brain foundation model requires huge amounts of data to capture common patterns and features. 'The beauty of a foundation model is the same way ChatGPT can generalize text, it can adapt to your tone, it can adapt to your way of writing—our model is able to adapt to the brains of different people,' Sakellariou says. Currently, the Cleveland Clinic and Piramidal team is using retrospective patient data to fine tune the model. In the next six to eight months, they plan to test the model in a tightly controlled ICU environment with live patient data and a limited number of beds and doctors. From there, they aim to slowly roll out the software to the entire ICU. Eventually, the software will allow the hospital system to monitor hundreds of patients at once, Najm says. The slow rollout is to reduce the rate of false positives and false negatives—instances where the system misidentifies patients who don't have a severe event or failing to catch someone who does. The latter scenario especially is 'a big problem that keeps us awake at night,' Najm says. Piramidal did not comment on the model's current accuracy but said it has evaluated its technology against a network of doctors and has achieved 'human-like' performance. The company plans to publish data on the model's accuracy at a future date. While Piramidal's immediate focus is applying its brain foundation model to the ICU, Sakellariou and Pahuja also want to use it for epilepsy and sleep monitoring. Meanwhile, brain-computer interface company Synchron is developing a brain foundation model incorporating data from trial participants to make its system more accurate and generalizable to more users. There are also consumer applications of brain foundation models, such as using EEG earbuds to measure emotional states. Both medical and consumer applications raise questions about how brain data will be used and stored, as well as how and when it should be used. 'Advancements like this one highlight the need for anticipatory ethical frameworks that support responsible development and use of these technologies,' says Caroline Montojo, president and CEO of the Dana Foundation, a private philanthropic organization dedicated to neuroscience research. 'It's critical to bring in many different perspectives at early stages of technology design from multiple disciplines, including ethicists, social scientists, and legal scholars, as well as the lived experiences of patients.'
New York Post
3 days ago
- New York Post
Trump can rein in healthcare costs AND win medical breakthroughs — here's how
Of all the problems bedeviling the American healthcare system, the high cost of pharmaceuticals is one of those most commonly cited by patients. Polling finds that most Americans think drugs are too expensive, and they're often right — even if pricey medications beat alternatives like surgery, hospitalization or living with pain. President Donald Trump has promised to implement healthcare reforms that both increase innovation and improve affordability. Advertisement Some see these as contradictory pursuits — but when it comes to pharmaceuticals, both of the president's goals can be achieved at the same time. This week the two of us, along with a team of top health and economic experts, launched Most Favored Patients, a working group aimed at developing reforms that will lower drug prices in ways that won't hinder or delay new drug development. Before we suggest policies that could work, let's be clear about what doesn't: government-mandated price controls. Advertisement Top-down edicts that remove the profit motive from drug research and development will do more harm than good, impeding the race to identify cures for cancer, Alzheimer's, Parkinson's, epilepsy and other cruel diseases. It's a short-sighted solution, too: It ignores the reality that 93% of US prescriptions are for very cheap generics — indeed, cheaper here than abroad — that emerge after innovators earn the necessary returns on their investments. Instead, let's try some innovations that make both medical and economic sense. First, do the easy stuff first and allow patients to buy medicines from pharmaceutical companies directly. Advertisement Our recent poll of 1,000 battleground-state voters found overwhelming 86% support for this concept, which would lower drug prices by avoiding expensive retail markups imposed by insurance companies and others. Most voters also favor Trump's intention to rein in costly middlemen like the highly concentrated pharmacy benefit manager industry, which negotiates drug prices for insurance companies. We also must require foreign countries to pay their fair share for medical innovations developed in the United States — that is, nearly all of them. Trump can use his NATO negotiations as a model here: Just as he has required Europe to pony up more for the benefits of NATO security through minimum levels of military spending, he could convince trading partners to spend more of their GDP on new drugs. Advertisement Right now, more than 70% of global pharmaceutical earnings come from the United States, even though we generate less than a quarter of global GDP. We annually spend $13,000 on healthcare per capita, while the rest of the developed world spends far less than $10,000 — partly because we allow more free-market healthcare pricing than other nations do. Trump is already implementing some of these reforms in his America First trade deals, securing some $300 billion worth of foreign commitments for new domestic pharmaceutical R&D, manufacturing and workforce investments. These commitments share the burden of finding cures that will benefit all of humanity — while fueling the American research engine that justifies the investments. Next, the Food and Drug Administration must thoroughly overhaul its antique, snail's-pace drug approval process: Many potential wonder drugs developed by small biomedical firms are shelved when that process' exorbitant costs and delays drain their capital. The FDA should fast-track experimental drugs for crippling and lethal diseases, and should expedite 'Right To Try' rules to get promising drugs to the people who need them. In addition, we believe the FDA should loosen its regulations and use economic criteria, not just clinical ones, to determine whether a drug may be fast-tracked for approval: Put simply, cheaper drugs should be allowed to come to market faster. Advertisement Finally, we're confident that price transparency in drugs and all other medical services would help drive prices down and encourage more comparison-shopping by patients. We don't buy food or gas or homes without knowing their price — but that's too often the case with drugs, hospitals and medical procedures. Republicans have been missing out on the political benefits of seizing on common-sense reforms like these. Advertisement Voters consistently view the GOP as being less caring and less reliable on solving our nation's healthcare concerns. That's made them cower. They keep their mouths shut and flee from any discussion of voters' valid complaints — and often lose elections as a result. As the midterms approach, Republicans who promote innovation with our Most Favored Patient proposals will help bring down costs, ensure American biomedical innovative supremacy, and save lives. Advertisement Everyone is on board with that. Stephen Moore is a co-founder of Unleash Prosperity, where Tomas Philipson is a senior research fellow.
Los Angeles Times
3 days ago
- Los Angeles Times
Polyglutamic Acid vs. Hyaluronic Acid: Which is More Hydrating?
LA Times Studios may earn commission from purchases made through our links. Both hyaluronic acid (HA) and polyglutamic acid (PGA) are superstars for hydration, but they work in distinctly different ways. And together, they're a game-changing duo for late summer and fall skin. Hyaluronic acid is famous for holding up to 1,000 times its weight in water, delivering instant plumpness but sometimes leaving skin feeling sticky or prone to moisture loss, especially as the air gets drier. Polyglutamic acid ups the ante. Research says it can hold up to four times more moisture than HA, but that it works differently. It forms an invisible, breathable film on the skin's surface that locks in hydration and strengthens the barrier against environmental stress, even slowing the enzymes that break down HA. Where HA draws moisture into the skin, PGA helps keep it there. Dermatologists now recommend layering both: HA as the inner hydrator, PGA as the outer seal. This double-hit routine not only boosts dewiness but also helps calm sensitivity, support skin resilience, and keep your glow going strong through seasonal shifts. Still loyal to that trusty hyaluronic acid serum every time your skin cries out for moisture? You're in good company. This molecule has dominated the hydration game for a decade, becoming the poster child for 'dewy' skin among beauty insiders and dermatologists alike. But new sets of hydrators are quietly changing the rules. Now, it's all about ingredients that flex with your life, protect your barrier, and make your glow more resilient than ever. As humidity drops and temperatures fluctuate, your skin's barrier gets stressed, making traditional hydration strategies less effective. 'Skin hydration isn't just about adding water, it's about holding onto it,' explains board-certified dermatologist Dr. Hope Mitchell. Polyglutamic acid is a next-gen hydrator with real staying power. Think of it as a lightweight, breathable shield that locks in moisture right at the surface, so your skin doesn't lose it to the dry, swirling fall air. 'Polyglutamic acid is a larger molecule,' Dr. Mitchell explains. 'It sits on top of the skin, forming a breathable film that locks in water while still hydrating.' PGA forms a protective film, reducing transepidermal water loss and helping skin stay plump and resilient, even as the seasons flip. Translation? More bounce and fewer fine lines. Snow mushroom (aka tremella), on the other hand, works differently and acts like tiny water magnets…drawing hydration into the skin. K-beauty devotees have nicknamed it 'nature's hyaluronic acid,' but new research shows its unique polysaccharides may keep skin hydrated even longer than synthetic HA, especially when your skin barrier is stressed Mitchell explains that snow mushroom can be exceptionally soothing when the skin transitions from humid heat to drier fall air. It's tempting to ditch heavy creams as the weather cools, but here's the fall update: lighter layers still rule, but with a focus on barrier support. Swap your thickest balms for hydrating essences and water-light serums that feature polyglutamic acid and tremella. Lock everything in with a gel-cream packed with ceramides — this minimalist layering helps sensitive skin handle both humidity and dryness. This is the moment for skin barrier repair. When your face feels tight, itchy, or just out of sorts as the air shifts, the real culprit is usually a compromised barrier. Experts say that proper hydration is essential for supporting skin structure and delivering nutrients to skin cells which is why combining hydrators like PGA and tremella with barrier boosters like niacinamide is key for smoother, calmer skin through seasonal changes. The changing season isn't just about moisture but about gentle actives like bakuchiol and azelaic acid to help you keep your glow without the risk of irritation. Bakuchiol evens out tone and smooths lines, while azelaic acid tackles redness and brightens stubborn spots. The new science of skin hydration is that you now get to pick ingredients that align with your barrier and calendar. Click here to learn more about No7 Beauty
